TOKYO—
Cellusion Inc. a regenerative medicine start-up company developing a novel cell therapy product for bullous keratopathy, applied in about half of corneal transplantation cases, announced that it has raised 2.83 billion yen ($21 million) in Series C Round financing.
Read more...